Biomarkers in pancreatic adenocarcinoma: current perspectives

Biomarkers in pancreatic adenocarcinoma: current perspectives

Douglas S Swords, Matthew A Firpo, Courtney L Scaife, Sean J Mulvihill Department of Surgery, University of Utah Health Sciences, Salt Lake City, UT, USA Abstract: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of 7.7%. Most patients are diagnose...

Full description

Bibliographic Details
Main Authors:	Swords DS, Firpo MA, Scaife CL, Mulvihill SJ
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-12-01
Series:	OncoTargets and Therapy
Subjects:	Pancreatic cancer biomarkers screening CA 19-9 CEA
Online Access:	https://www.dovepress.com/biomarkers-in-pancreatic-adenocarcinoma-current-perspectives-peer-reviewed-article-OTT

Similar Items

The Role Of Tumor Markers In The Diagnosis And Follow Up In Patients With Pancreatic Cancer
by: Ansam Aladdin Al-Bayatti
Published: (2007-01-01)

Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer
by: Hsu Wu, et al.
Published: (2019-07-01)

Correlation Between Baseline Serum Tumor Markers and Clinical Characteristic Factors in Patients with Advanced Pancreatic Cancer
by: Deng G, et al.
Published: (2020-11-01)

Value of CA19-9, CA125 and CEA combined magnetic resonance imaging in the diagnosis of pancreatic cancer
by: Ying Huang, et al.
Published: (2018-02-01)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
by: Shreya Mehta, et al.
Published: (2021-07-01)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
by: Shreya Mehta, et al.
Published: (2021-10-01)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
by: Seifeldin Awad, et al.
Published: (2020-05-01)

Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites
by: Fang Liu, et al.
Published: (2014-05-01)

Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
by: Leilani Lakemeyer, et al.
Published: (2021-03-01)

Rare primary peritoneal mucinous adenocarcinoma in a 69‐year‐old man
by: Fumiko Satoh, et al.
Published: (2021-09-01)

Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges
by: Alex Root, et al.
Published: (2018-03-01)

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
by: Kaisa Lehtomäki, et al.
Published: (2021-08-01)

Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients
by: Martin Pesta, et al.
Published: (2019-06-01)

Synergistic Association of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 on the Risk of Abnormal Glucose Regulation
by: Cheng YC, et al.
Published: (2020-06-01)

Fusion Expression and Affinity Identification of Two scFvs Against CEA or CA19-9 in HEK293 Cells
by: LU Wenbin, et al.
Published: (2019-01-01)

Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0–I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
by: Song JY, et al.
Published: (2018-08-01)

CEA, CA19-9 & A-FP as tumor markers for colorectal carcinoma
by: Ansam A. AL-Bayatti, et al.
Published: (2006-04-01)

The effect of glycemic control on CEA, CA 19-9, amylase and lipase levels
by: Ata Naim, et al.
Published: (2014-09-01)

Kolorektal Kanserlerin Tanı ve Prognostik Takibinde Eski ve Yeni Serum Biyobelirteçleri: Sistematik İnceleme ve Meta-Analiz
by: Muhammed Zübeyr Üçüncü
Published: (2019-12-01)

Early Diagnosis of Pancreatic Cancer: The Key for Survival
by: Gina Gheorghe, et al.
Published: (2020-10-01)

Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9
by: Haidy Nasief, et al.
Published: (2020-01-01)

Diagnostic Significance of Serum IgG Galactosylation in CA19-9-Negative Pancreatic Carcinoma Patients
by: Ailing Zhong, et al.
Published: (2019-02-01)

CA 19-9 levels in patients with acute pancreatitis due to gallstone and metabolic/toxic reasons
by: Omer Burcak Binicier, et al.

Xanthogranulomatous Pancreatitis -A Rare Case Defying Clinical, Radiological and Tumor Marker Diagnostics with a Review of Literature
by: Kavita GAUR, et al.
Published: (2019-05-01)

Raised CA19-9 in Autoimmune Pancreatitis
by: Sridhar Sundaram, et al.
Published: (2020-05-01)

A rare case of PSA-negative metastasized prostate cancer to the stomach with serum CEA and CA19-9 elevation: a case report
by: Koji Shindo, et al.
Published: (2020-12-01)

Diagnostic Value of FH Test for Early Screening of Rectal Cancer
by: MA Qian, et al.
Published: (2019-04-01)

Raised CA19–9 and CEA have prognostic relevance in gallbladder carcinoma
by: Ashish Sachan, et al.
Published: (2020-08-01)

Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and ca 19-9 as apoptotic markers; a comparative study
by: Mahgoub Samir S, et al.
Published: (2011-07-01)

Predictive biomarkers in chemotherapy of pancreatic duct adenocarcinoma: rewiew of the literature
by: Z A Kovalenko, et al.
Published: (2016-06-01)

Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer
by: Jiayu Zhang, et al.
Published: (2020-02-01)

Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance
by: Fuxin Jia, et al.
Published: (2019-09-01)

Malignant Melanoma Arising in an Ovarian Mature Cystic Teratoma - A Rare Entity
by: RANJINI KUDVA, et al.
Published: (2015-04-01)

Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer
by: Ko Tomishima, et al.
Published: (2021-08-01)

Metastatic prostate cancer with elevated serum levels of CEA and CA19-9
by: Guang-Dar Juang, et al.
Published: (2014-03-01)

Difference between carbohydrate antigen 19‐9 and fluorine‐18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual‐center study
by: Hirofumi Akita, et al.
Published: (2021-05-01)

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
by: Ben George, et al.
Published: (2021-10-01)

CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer
by: Y. Chen, et al.
Published: (2019-08-01)

Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma
by: John C. Chang, et al.
Published: (2017-03-01)

Role of Urinary and Serum Carbohydrate Antigen 19-9 as a Biomarker in Diagnosis of Adult Giant Hydronephrosis
by: Indraneel Banerjee, et al.
Published: (2016-09-01)